Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has issued an update.
On December 30, 2025, Gasherbrum Bio, a subsidiary of Structure Therapeutics, entered into a non-exclusive licensing agreement with Genentech and Roche, granting them rights under certain Gasherbrum patents covering a distinct class of oral GLP-1 receptor agonists to develop and commercialize products containing Genentech’s proprietary compound CT-996. In return, Gasherbrum will receive a one-time $100 million payment within 30 days of signing and low single-digit royalties on net sales of CT-996 products until the relevant patents expire or a specified earlier date, while retaining full control over its own metabolic pipeline, as the license expressly does not encumber Structure’s ongoing programs, including aleniglipron and other GLP-1, dual amylin/calcitonin, and GIPR/GCGR modulators, and preserves Gasherbrum’s ability to terminate the deal in the event of material breach or patent challenges, providing a significant non-dilutive capital infusion without ceding broader strategic or patent prosecution rights.
The most recent analyst rating on (GPCR) stock is a Hold with a $73.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.
Spark’s Take on GPCR Stock
According to Spark, TipRanks’ AI Analyst, GPCR is a Neutral.
The score is driven primarily by strong technical momentum and a well-capitalized, low-debt balance sheet, supported by a positive clinical-trial event. These positives are tempered by the lack of revenue, widening losses, and substantial ongoing cash burn, alongside limited support from traditional valuation metrics.
To see Spark’s full report on GPCR stock, click here.
More about Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., through its wholly owned subsidiary Gasherbrum Bio, Inc., operates in the biopharmaceutical industry with a focus on developing small-molecule metabolic and endocrine therapies, including oral GLP-1 receptor agonists, dual amylin and calcitonin receptor agonists such as ACCG-2671 and ACCG-3535, and modulators of GIPR and GCGR.
Average Trading Volume: 1,500,114
Technical Sentiment Signal: Buy
Current Market Cap: $4.13B
See more insights into GPCR stock on TipRanks’ Stock Analysis page.